HONG KONG–(BUSINESS WIRE)–CSOP Asset Management Limited (“CSOP”), a Hong Kong-based ETF manager that specializes in providing China-access strategies, has announced the reorganization of the CSOP FTSE China A50 ETF (ticker: AFTY) (the “ETF”). CSOP has established a strategic relationship with Pacer ETFs (“Pacer”) on the ongoing distribution and management of AFTY. The reorganization of AFTY also marks the partnership established between the two companies.
Pacer has made the acquisition of AFTY, moving the fund from the original CSOP ETF Trust to the Pacer Funds Trust. After the reorganization, AFTY is renamed Pacer CSOP FTSE China A50 ETF. Pacer Advisors, Inc (“Pacer Advisors”) becomes the investment adviser to the Fund, whereas CSOP retains the responsibility of day-to-day management of the Fund’s portfolio, as the Fund’s investment sub-adviser. The investment objective, policies, strategy, risks, as well as listing exchange (NYSE Arca) and ticker symbol (AFTY) all remain unchanged.
The Pacer CSOP FTSE China A50 ETF (AFTY) seeks to track the FTSE China A50 Net Total Return Index and offers exposure to the 50 largest companies in the China A-Shares market. This index only tracks A-Shares which are distinct in that only companies incorporated in Mainland China and listed on the Shanghai or Shenzhen exchanges are included.
“We see this as a win-win collaboration, where CSOP and Pacer each plays to its strength in managing A-Shares portfolio and in wholesale and distribution efforts respectively,” says Melody He, Managing Director and Head of Business Development of CSOP. “We believe that combining the strength of the two firms will bring benefits of economies of scale to our investors, and we look forward to working with the Pacer team to go out and speak to wholesalers and independent advisors about the China investment story.”
“While many of our peers have turned passive on the overseas market growth such as in US and Europe, we remain committed to establishing our foothold in these markets,” comments Chen Ding, CEO of CSOP. “As China continues to open up its capital market to foreign investors, more and more investors, institutions and retails alike, find it necessary to build out dedicated China exposure in their investment portfolio. As a China specialist, we are committed to bringing different China strategies to meet their specific needs.”
For further details, including the risk factors, please refer to the respective offering documents.
About CSOP Asset Management Limited
CSOP Asset Management Limited (“CSOP”) was founded in 2008 as the first offshore asset manager set up by a regulated asset management company in China. With a dedicated focus on China investing, CSOP manages public and private funds, as well as providing investment advisory services to Asian and global investors. In addition, CSOP is also best known as an ETF leader in Asia. As of 31 Dec 2019, CSOP had US$ 6 billion in assets under management.
Risk Disclaimer:
Before investing you should carefully consider the ETF’s investment objectives, risks, charges, and expenses. Please read the prospectus carefully before investing. A copy may be obtained by visiting https://www.paceretfs.com/products/afty.
Pacer Advisors, Inc. is the fund advisor. CSOP Asset Management LTD is the fund sub-adviser. CSOP Asset Management LTD is registered as an investment advisor with the SEC.
Contacts
Contacts: Annie Shum
CSOP Asset Management Limited
+852-3406 5638
annie.shum@csopasset.com
Larry Wang
CSOP Asset Management Limited
+852 3406 5613
larry.wang@csopasset.com
HOHHOT, CHINA - Media OutReach Newswire - 23 December 2024 - China's National Forestry and…
HONG KONG SAR - EQS Newswire - 23 December 2024 - Novautek Autonomous Driving Limited…
JAKARTA, INDONESIA - Media OutReach Newswire - 23 December 2024 - V-GREEN and PT Xanh…
Increase in opportunities predicted for high-speed optical transceivers and miniaturized connectivity solutions to address data-intensive…
HONG KONG SAR - Media OutReach Newswire - 23 December 2024 - DYXnet, a wholly-owned…
CAIRO, EGYPT - Media OutReach Newswire - 23 December 2024 - Eand, Novo Nordisk, BSH,…